The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Blackwell, K, Gligorov, J, Jacobs, I et al. (1 more author) (2018) The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Clinical Breast Cancer, 18 (2). pp. 95-113. ISSN 1526-8209

Abstract

Metadata

Authors/Creators:
  • Blackwell, K
  • Gligorov, J
  • Jacobs, I
  • Twelves, C
Copyright, Publisher and Additional Information: (c) 2018, The Authors. Published by Elsevier Inc. This is an open access articleunder the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Access to biologic therapy; Adjuvant; HER2-targeted therapy; Metastatic; Neoadjuvant
Dates:
  • Accepted: 17 January 2018
  • Published (online): 2 February 2018
  • Published: April 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 15 Jul 2019 15:22
Last Modified: 15 Jul 2019 15:22
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.clbc.2018.01.006

Share / Export

Statistics